FDA Accepts Koutif Therapeutics’ Investigational New Drug Application for KT-1002

FDA Accepts Koutif Therapeutics’ Investigational New Drug Application for KT-1002
The U.S. Food and Drug Administration (FDA) has accepted Koutif Therapeutics' investigational new drug (IND) application for KT-1002. The company is set to begin a Phase 1 clinical trial testing the experimental therapy in inflammatory bowel disease (IBD). The trial will assess how the oral therapy behaves inside the body and if it is safe and effective against IBD. Koutif also expects to determine the optimal dose of KT-1002.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *